Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 5/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926775 | 0.94 | MCHR1 (0.56) | KIFC1CDK2GPR34GPR132MCHR1 | |
| SCHEMBL3999271 | 0.91 | GPR34 (0.58) | KIFC1CDK2GPR34GPR132MME | |
| SCHEMBL5927190 | 0.89 | KIFC1 (0.61) | KIFC1CDK2GPR34GPR132MCHR1 | |
| SCHEMBL3996979 | 0.89 | SCN9A (0.51) | KIFC1CDK2GPR34GPR132MCHR1 | |
| SCHEMBL8338544 | 0.88 | KIFC1 (0.53) | KIFC1CDK2GPR34GPR132MCHR1 | |
| SCHEMBL5927607 | 0.87 | KIFC1 (0.57) | KIFC1CDK2GPR34GPR132FPR2 | |
| SCHEMBL3993238 | 0.86 | SCN9A (0.48) | KIFC1CDK2GPR34GPR132MCHR1 | |
| SCHEMBL8337225 | 0.86 | FPR2 (0.54) | KIFC1CDK2GPR34GPR132FPR2 | |
| SCHEMBL5927478 | 0.85 | MME (0.55) | MMEACECPA1ACE2PIN1 | |
| SCHEMBL5926779 | 0.85 | MME (0.50) | GPR34MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | KIFC1 3927/4885CDK2 2502/4885GPR34 4618/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | KIFC1 4489/4885CDK2 1006/4885GPR34 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.